Merus NV (MRUS) Actualités

Merus and Biohaven Announce Collaboration to Co-Develop Three Novel Bispecific ADC Programs

NEW HAVEN, Conn. and UTRECHT, The Netherlands and CAMBRIDGE, Mass., Jan. 12, 2025 (GLOBE NEWSWIRE...

Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors

Merus announces First Patient Dosed in Phase 2 Trial of Petosemtamab in 3L+ mCRC

UTRECHT, The Netherlands and CAMBRIDGE, Mass., Dec. 16, 2024 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS), a...

Merus’ Petosemtamab Monotherapy Interim Data Continues to Demonstrate Clinically Meaningful Activity in 2L+ r/m HNSCC

Petosemtamab in combination with pembrolizumab in 1L r/m PD-L1 expressing HNSCC ongoing with clinical data...

Form 8-K - Current report

Merus Announces FDA Approval of BIZENGRI® (zenocutuzumab-zbco) for NRG1+ Pancreatic Adenocarcinoma and NRG1+ Non–Small Cell Lung Cancer (NSCLC) Based on Safety and Efficacy Data From the eNRGy Study

BIZENGRI® is the first and only therapy approved by the FDA specifically for pancreatic adenocarcinoma and...

Form 8-K - Current report

Merus and Partner Therapeutics Announce License Agreement for the U.S. Commercialization of Zenocutuzumab in NRG1 Fusion-Positive Cancer

UTRECHT, The Netherlands and CAMBRIDGE, Mass., Dec. 02, 2024 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS...

Merus Announces Publication of an Abstract on Petosemtamab as 2L+ treatment of r/m HNSCC at the ESMO Asia Congress 2024

– Petosemtamab 1500 mg monotherapy phase 2 interim data continues to demonstrate clinically meaningful activity...

Form 8-K - Current report

Merus Receives FDA extension of PDUFA for zenocutuzumab

UTRECHT, The Netherlands and CAMBRIDGE, Mass., Nov. 05, 2024 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS...

Merus Announces Financial Results for the Third Quarter 2024 and Provides Business Update

Phase 3 registrational trials evaluating petosemtamab in combination with pembrolizumab in 1L and petosemtamab...

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Merus Announces First Patient Dosed in LiGeR-HN1, a Phase 3 Trial Evaluating Petosemtamab in Combination with Pembrolizumab in 1L r/m HNSCC

UTRECHT, The Netherlands and CAMBRIDGE, Mass., Sept. 30, 2024 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS...

Merus Announces Abstract Accepted for Presentation at the ESMO Asia Congress 2024

UTRECHT, The Netherlands and CAMBRIDGE, Mass., Sept. 17, 2024 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS...